Advice
following a full submission
adalimumab (Humira®) is accepted for use within NHS Scotland.
Indication under review: treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adult patients with an inadequate response to conventional systemic HS therapy.
Evidence from two double-blind, randomised studies demonstrated significant reductions in inflammatory lesions and no worsening of abscesses and draining fistulas at 12 weeks with adalimumab compared with placebo.
Download detailed advice193KB (PDF)
Medicine details
- Medicine name:
- adalimumab (Humira)
- SMC ID:
- 1143/16
- Indication:
- Treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adult patients with an inadequate response to conventional systemic HS therapy.
- Pharmaceutical company
- AbbVie Ltd
- BNF chapter
- Skin
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 09 May 2016